Pristinamycin (CAS 270076-60-3)

Pristinamycin, an antibiotic drug belonging to the macrolide class, displays synergistic antibacterial action. It has been effectively employed since the early 1960s for the treatment of various bacterial infections. This compound inhibits bacterial growth by impeding the production of essential proteins necessary for their survival. Furthermore, Pristinamycin possesses anti-inflammatory properties, rendering it beneficial for managing certain inflammatory conditions. Extensively used in scientific research, Pristinamycin has contributed to investigations on bacterial antibiotic resistance, the development of novel antibiotics, and the exploration of existing antibiotics′ mechanisms of action. It has also facilitated studies concerning the impact of antibiotics on human cells and the formulation of new treatments for bacterial infections. Pristinamycin achieves its antibacterial effect by binding to the 50S ribosomal subunit of bacteria, hindering peptide bond formation between amino acids and thereby obstructing protein synthesis. Consequently, bacterial replication is impeded, leading to their demise.

References:

1. Novel pristinamycin-responsive expression systems for plant cells.  |  Frey, AD., et al. 2001. Biotechnol Bioeng. 74: 154-63. PMID: 11370004
2. Pristinamycin for Enterococcus faecium resistant to vancomycin and gentamicin.  |  Wade, J., et al. 1992. Lancet. 339: 312-3. PMID: 1346324
3. Improved production of pristinamycin coupled with an adsorbent resin in fermentation by Streptomyces pristinaespiralis.  |  Jia, B., et al. 2006. Biotechnol Lett. 28: 1811-5. PMID: 16912920
4. From foreign pharmacopoeias: ′new′ antibiotics from old?  |  Hamilton-Miller, JM. 1991. J Antimicrob Chemother. 27: 702-5. PMID: 1938680
5. Conjugal transferring of resistance gene ptr for improvement of pristinamycin-producing Streptomyces pristinaespiralis.  |  Jin, Z., et al. 2010. Appl Biochem Biotechnol. 160: 1853-64. PMID: 19629757
6. Glycine feeding improves pristinamycin production during fermentation including resin for in situ separation.  |  Zhang, LJ., et al. 2012. Bioprocess Biosyst Eng. 35: 513-7. PMID: 21947672
7. Emergence of Staphylococcus aureus strains resistant to pristinamycin in Sfax (Tunisia).  |  Mezghani Maalej, S., et al. 2012. Pathol Biol (Paris). 60: e71-4. PMID: 22265593
8. In-vitro activity of pristinamycin and its components against gram-negative anaerobic bacilli and Gardnerella vaginalis.  |  Weber, P., et al. 1989. J Antimicrob Chemother. 23: 825-30. PMID: 2503487
9. The basophil activation test: a sensitive test in the diagnosis of allergic immediate hypersensitivity to pristinamycin.  |  Viel, S., et al. 2015. Int Arch Allergy Immunol. 167: 94-8. PMID: 26202178
10. Development and Validation of a Stability-Indicating RP-HPLC Method for the Assay of Pristinamycin in Bulk and Tablet Dosage Form.  |  Mallikarjuna Rao, N. and Gowrisankar, D. 2016. Sci Pharm. 84: 279-87. PMID: 27222604
11. Pristinamycin production using Streptomyces pristinaespiralis and date sirup as substrate-process modeling, optimization, and scale-up.  |  Aleid, SM., et al. 2022. Prep Biochem Biotechnol. 52: 1044-1050. PMID: 35037553
12. Production, separation, and antimicrobial activity assessment of pristinamycin produced using date fruit extract as substrate.  |  Hamad, SH., et al. 2022. J Adv Pharm Technol Res. 13: 161-165. PMID: 35935699